| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 230 | 2025 | 571 | 28.790 |
Why?
|
| Cerebellar Neoplasms | 172 | 2025 | 461 | 22.870 |
Why?
|
| Brain Neoplasms | 107 | 2025 | 1406 | 9.830 |
Why?
|
| Ependymoma | 41 | 2024 | 176 | 7.670 |
Why?
|
| Hedgehog Proteins | 70 | 2025 | 268 | 6.670 |
Why?
|
| Gene Expression Regulation, Neoplastic | 87 | 2025 | 2137 | 4.240 |
Why?
|
| Neoplastic Stem Cells | 29 | 2025 | 352 | 3.720 |
Why?
|
| Glioma | 22 | 2022 | 535 | 3.510 |
Why?
|
| Biomarkers, Tumor | 44 | 2025 | 1721 | 2.860 |
Why?
|
| DNA Methylation | 47 | 2024 | 1148 | 2.420 |
Why?
|
| Wnt Proteins | 23 | 2021 | 226 | 2.380 |
Why?
|
| Infratentorial Neoplasms | 16 | 2024 | 48 | 2.320 |
Why?
|
| Mutation | 64 | 2025 | 6342 | 2.070 |
Why?
|
| Glioblastoma | 17 | 2025 | 372 | 2.020 |
Why?
|
| Neoplasm Recurrence, Local | 23 | 2025 | 1316 | 2.020 |
Why?
|
| Gene Expression Profiling | 58 | 2025 | 1922 | 2.010 |
Why?
|
| Epigenesis, Genetic | 24 | 2023 | 771 | 2.000 |
Why?
|
| Humans | 374 | 2025 | 134145 | 1.950 |
Why?
|
| Cell Proliferation | 65 | 2025 | 2562 | 1.890 |
Why?
|
| Epigenomics | 13 | 2023 | 196 | 1.820 |
Why?
|
| Neoplasm Metastasis | 20 | 2023 | 745 | 1.770 |
Why?
|
| Cell Line, Tumor | 69 | 2025 | 3799 | 1.760 |
Why?
|
| Mice | 130 | 2025 | 19043 | 1.700 |
Why?
|
| Signal Transduction | 68 | 2025 | 4936 | 1.690 |
Why?
|
| Transcriptome | 29 | 2025 | 1135 | 1.680 |
Why?
|
| Neural Stem Cells | 18 | 2022 | 152 | 1.600 |
Why?
|
| Tumor Suppressor Protein p53 | 24 | 2025 | 795 | 1.570 |
Why?
|
| Animals | 156 | 2025 | 36518 | 1.560 |
Why?
|
| Genomics | 24 | 2025 | 1678 | 1.560 |
Why?
|
| Child | 147 | 2025 | 25911 | 1.550 |
Why?
|
| MicroRNAs | 21 | 2023 | 949 | 1.520 |
Why?
|
| Molecular Targeted Therapy | 16 | 2019 | 407 | 1.520 |
Why?
|
| Neoplasms | 18 | 2025 | 3034 | 1.480 |
Why?
|
| Prognosis | 55 | 2025 | 5084 | 1.410 |
Why?
|
| Meningeal Neoplasms | 9 | 2025 | 217 | 1.390 |
Why?
|
| Cerebellum | 24 | 2025 | 467 | 1.370 |
Why?
|
| Histones | 18 | 2025 | 572 | 1.300 |
Why?
|
| Child, Preschool | 95 | 2025 | 14895 | 1.250 |
Why?
|
| Central Nervous System Neoplasms | 8 | 2025 | 216 | 1.200 |
Why?
|
| Proto-Oncogene Proteins c-myc | 13 | 2024 | 218 | 1.180 |
Why?
|
| Transcription Factors | 25 | 2025 | 2734 | 1.160 |
Why?
|
| Neoplasm Proteins | 15 | 2021 | 719 | 1.070 |
Why?
|
| DNA Copy Number Variations | 17 | 2025 | 1036 | 1.060 |
Why?
|
| Astrocytoma | 8 | 2022 | 112 | 1.020 |
Why?
|
| Cell Transformation, Neoplastic | 17 | 2022 | 645 | 1.010 |
Why?
|
| Xenograft Model Antitumor Assays | 27 | 2025 | 1013 | 0.990 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2025 | 827 | 0.980 |
Why?
|
| Female | 148 | 2025 | 72003 | 0.970 |
Why?
|
| Choroid Plexus Neoplasms | 5 | 2019 | 18 | 0.940 |
Why?
|
| Male | 137 | 2025 | 66171 | 0.920 |
Why?
|
| Infant | 66 | 2025 | 13256 | 0.920 |
Why?
|
| Proto-Oncogene Proteins | 14 | 2019 | 625 | 0.900 |
Why?
|
| Tumor Microenvironment | 9 | 2025 | 699 | 0.890 |
Why?
|
| Antineoplastic Agents | 21 | 2022 | 1853 | 0.890 |
Why?
|
| Adolescent | 84 | 2025 | 20643 | 0.880 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 7 | 2019 | 97 | 0.880 |
Why?
|
| Chromatin | 13 | 2025 | 617 | 0.880 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2015 | 1070 | 0.860 |
Why?
|
| Cranial Fossa, Posterior | 4 | 2016 | 20 | 0.860 |
Why?
|
| Telomerase | 9 | 2021 | 179 | 0.840 |
Why?
|
| Rhabdoid Tumor | 7 | 2019 | 56 | 0.820 |
Why?
|
| Nuclear Proteins | 18 | 2019 | 1351 | 0.810 |
Why?
|
| Transposases | 5 | 2024 | 45 | 0.800 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2020 | 1357 | 0.770 |
Why?
|
| Nerve Tissue Proteins | 15 | 2025 | 1167 | 0.770 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 7 | 2024 | 405 | 0.760 |
Why?
|
| Polycomb Repressive Complex 1 | 8 | 2020 | 36 | 0.750 |
Why?
|
| Gene Expression Regulation, Developmental | 6 | 2024 | 1051 | 0.730 |
Why?
|
| Cell Differentiation | 18 | 2025 | 2043 | 0.730 |
Why?
|
| Oncogenes | 10 | 2024 | 181 | 0.730 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2021 | 3508 | 0.710 |
Why?
|
| Craniospinal Irradiation | 7 | 2019 | 66 | 0.710 |
Why?
|
| Germ-Line Mutation | 8 | 2023 | 370 | 0.710 |
Why?
|
| Fetus | 3 | 2022 | 601 | 0.700 |
Why?
|
| Cell Lineage | 11 | 2025 | 370 | 0.690 |
Why?
|
| Hydrocephalus | 3 | 2024 | 276 | 0.680 |
Why?
|
| Repressor Proteins | 12 | 2022 | 874 | 0.680 |
Why?
|
| Genome, Human | 17 | 2024 | 1350 | 0.680 |
Why?
|
| Lipocalin-2 | 1 | 2020 | 32 | 0.670 |
Why?
|
| Evolution, Molecular | 3 | 2019 | 710 | 0.670 |
Why?
|
| Mice, SCID | 19 | 2025 | 615 | 0.670 |
Why?
|
| Otx Transcription Factors | 5 | 2024 | 26 | 0.660 |
Why?
|
| Neuroglia | 3 | 2019 | 215 | 0.660 |
Why?
|
| Oncogene Proteins | 8 | 2018 | 157 | 0.660 |
Why?
|
| Metencephalon | 3 | 2025 | 11 | 0.660 |
Why?
|
| Kaplan-Meier Estimate | 21 | 2023 | 1144 | 0.650 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 99 | 0.650 |
Why?
|
| Gene Regulatory Networks | 13 | 2025 | 400 | 0.650 |
Why?
|
| DNA-Binding Proteins | 16 | 2019 | 2177 | 0.620 |
Why?
|
| Adult | 61 | 2024 | 31943 | 0.620 |
Why?
|
| Carrier Proteins | 10 | 2022 | 1075 | 0.610 |
Why?
|
| Promoter Regions, Genetic | 12 | 2021 | 1434 | 0.610 |
Why?
|
| Immunotherapy | 2 | 2022 | 749 | 0.610 |
Why?
|
| Disease Models, Animal | 22 | 2025 | 4802 | 0.610 |
Why?
|
| Genes, Tumor Suppressor | 7 | 2021 | 225 | 0.610 |
Why?
|
| Mice, Nude | 18 | 2019 | 780 | 0.610 |
Why?
|
| Motor Cortex | 1 | 2019 | 85 | 0.610 |
Why?
|
| Transcription, Genetic | 7 | 2020 | 1762 | 0.600 |
Why?
|
| Carcinoma | 3 | 2019 | 321 | 0.600 |
Why?
|
| Chromosome Aberrations | 8 | 2021 | 628 | 0.600 |
Why?
|
| Neuroectodermal Tumors, Primitive | 7 | 2019 | 56 | 0.600 |
Why?
|
| Cohort Studies | 30 | 2023 | 5219 | 0.590 |
Why?
|
| Brain Stem Neoplasms | 3 | 2017 | 47 | 0.590 |
Why?
|
| Single-Cell Analysis | 10 | 2025 | 356 | 0.590 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 190 | 0.580 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2017 | 30 | 0.580 |
Why?
|
| Neuroblastoma | 3 | 2025 | 551 | 0.580 |
Why?
|
| Immunohistochemistry | 20 | 2021 | 1764 | 0.580 |
Why?
|
| Benzazepines | 2 | 2015 | 61 | 0.570 |
Why?
|
| Young Adult | 38 | 2025 | 9960 | 0.560 |
Why?
|
| RNA, Long Noncoding | 5 | 2024 | 248 | 0.560 |
Why?
|
| RNA, Messenger | 14 | 2020 | 2915 | 0.560 |
Why?
|
| DEAD-box RNA Helicases | 8 | 2020 | 150 | 0.560 |
Why?
|
| Lysine | 5 | 2020 | 207 | 0.560 |
Why?
|
| Patched-1 Receptor | 12 | 2019 | 50 | 0.550 |
Why?
|
| Kv1.1 Potassium Channel | 4 | 2012 | 42 | 0.550 |
Why?
|
| In Situ Hybridization, Fluorescence | 11 | 2014 | 793 | 0.550 |
Why?
|
| Isocitrate Dehydrogenase | 5 | 2022 | 82 | 0.540 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2021 | 609 | 0.540 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 898 | 0.540 |
Why?
|
| Cell Cycle Proteins | 7 | 2019 | 709 | 0.530 |
Why?
|
| Alternative Splicing | 3 | 2024 | 379 | 0.530 |
Why?
|
| DNA Mutational Analysis | 15 | 2020 | 843 | 0.520 |
Why?
|
| Intelligence | 4 | 2019 | 107 | 0.520 |
Why?
|
| Survival Analysis | 17 | 2022 | 1595 | 0.510 |
Why?
|
| Tumor Cells, Cultured | 14 | 2020 | 1109 | 0.510 |
Why?
|
| Embryonic Stem Cells | 1 | 2017 | 178 | 0.510 |
Why?
|
| Cerebrum | 4 | 2022 | 37 | 0.510 |
Why?
|
| Teratoma | 5 | 2019 | 131 | 0.510 |
Why?
|
| Transforming Growth Factor beta | 6 | 2020 | 488 | 0.510 |
Why?
|
| Intracranial Aneurysm | 2 | 2020 | 84 | 0.500 |
Why?
|
| beta Catenin | 11 | 2019 | 232 | 0.500 |
Why?
|
| Neurogenesis | 7 | 2025 | 223 | 0.490 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 263 | 0.490 |
Why?
|
| Smoothened Receptor | 6 | 2019 | 34 | 0.490 |
Why?
|
| Apoptosis | 14 | 2019 | 1945 | 0.490 |
Why?
|
| Carcinogenesis | 7 | 2020 | 363 | 0.490 |
Why?
|
| N-Myc Proto-Oncogene Protein | 9 | 2019 | 65 | 0.490 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2015 | 18 | 0.490 |
Why?
|
| Membrane Proteins | 9 | 2019 | 1621 | 0.480 |
Why?
|
| Stem Cells | 6 | 2024 | 754 | 0.480 |
Why?
|
| Rhombencephalon | 3 | 2024 | 50 | 0.480 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2012 | 176 | 0.470 |
Why?
|
| Mutism | 3 | 2024 | 32 | 0.470 |
Why?
|
| Receptors, Atrial Natriuretic Factor | 3 | 2012 | 9 | 0.470 |
Why?
|
| Embryonic Structures | 2 | 2025 | 9 | 0.460 |
Why?
|
| Genetic Testing | 4 | 2018 | 1105 | 0.450 |
Why?
|
| Ventriculostomy | 1 | 2014 | 44 | 0.450 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2022 | 2949 | 0.450 |
Why?
|
| Neurosurgery | 3 | 2007 | 78 | 0.450 |
Why?
|
| Spinal Neoplasms | 1 | 2015 | 76 | 0.450 |
Why?
|
| Embolization, Therapeutic | 2 | 2020 | 225 | 0.450 |
Why?
|
| Pathology, Molecular | 2 | 2015 | 67 | 0.450 |
Why?
|
| Cancer Survivors | 4 | 2024 | 251 | 0.440 |
Why?
|
| Mice, Inbred NOD | 14 | 2021 | 318 | 0.440 |
Why?
|
| Genome | 4 | 2023 | 529 | 0.440 |
Why?
|
| Mice, Transgenic | 20 | 2021 | 2538 | 0.440 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 158 | 0.430 |
Why?
|
| Pyrimidines | 4 | 2016 | 419 | 0.430 |
Why?
|
| Proteomics | 7 | 2024 | 603 | 0.430 |
Why?
|
| Homeodomain Proteins | 7 | 2025 | 589 | 0.430 |
Why?
|
| Receptors, Cell Surface | 11 | 2014 | 497 | 0.420 |
Why?
|
| Neurons | 10 | 2025 | 2051 | 0.420 |
Why?
|
| Computational Biology | 11 | 2021 | 890 | 0.420 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 299 | 0.400 |
Why?
|
| Gene Amplification | 7 | 2017 | 247 | 0.400 |
Why?
|
| Kruppel-Like Transcription Factors | 5 | 2014 | 120 | 0.390 |
Why?
|
| DNA Helicases | 6 | 2020 | 253 | 0.390 |
Why?
|
| Receptors, G-Protein-Coupled | 5 | 2018 | 315 | 0.390 |
Why?
|
| Cluster Analysis | 10 | 2020 | 440 | 0.390 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 3 | 2020 | 9 | 0.390 |
Why?
|
| Disease-Free Survival | 13 | 2018 | 972 | 0.380 |
Why?
|
| DNA, Neoplasm | 4 | 2021 | 320 | 0.380 |
Why?
|
| Cell Movement | 14 | 2024 | 920 | 0.380 |
Why?
|
| Loss of Heterozygosity | 6 | 2021 | 135 | 0.380 |
Why?
|
| Genetic Engineering | 2 | 2019 | 165 | 0.370 |
Why?
|
| Clonal Evolution | 1 | 2012 | 49 | 0.370 |
Why?
|
| Chromosomes, Human, Pair 19 | 4 | 2019 | 65 | 0.370 |
Why?
|
| Unconsciousness | 1 | 2011 | 18 | 0.370 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2011 | 24 | 0.360 |
Why?
|
| Forkhead Transcription Factors | 5 | 2025 | 390 | 0.360 |
Why?
|
| Survival Rate | 12 | 2024 | 2212 | 0.350 |
Why?
|
| Consensus | 3 | 2024 | 728 | 0.350 |
Why?
|
| Up-Regulation | 11 | 2019 | 914 | 0.350 |
Why?
|
| Gene Rearrangement | 3 | 2020 | 331 | 0.340 |
Why?
|
| Neurofibromatosis 1 | 1 | 2011 | 65 | 0.340 |
Why?
|
| Patched Receptors | 11 | 2014 | 37 | 0.340 |
Why?
|
| DNA Mismatch Repair | 3 | 2022 | 54 | 0.340 |
Why?
|
| CpG Islands | 6 | 2018 | 347 | 0.330 |
Why?
|
| Retrospective Studies | 30 | 2024 | 17565 | 0.330 |
Why?
|
| Receptor, trkB | 2 | 2024 | 25 | 0.330 |
Why?
|
| Azure Stains | 1 | 2010 | 5 | 0.330 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 260 | 0.330 |
Why?
|
| Cadherins | 1 | 2011 | 186 | 0.330 |
Why?
|
| Precision Medicine | 4 | 2018 | 361 | 0.330 |
Why?
|
| Radiation Tolerance | 2 | 2025 | 67 | 0.330 |
Why?
|
| Chromosome Banding | 1 | 2010 | 140 | 0.320 |
Why?
|
| Histone Demethylases | 4 | 2022 | 43 | 0.320 |
Why?
|
| Cytogenetic Analysis | 3 | 2017 | 82 | 0.320 |
Why?
|
| Li-Fraumeni Syndrome | 3 | 2023 | 52 | 0.320 |
Why?
|
| Proto-Oncogene Proteins B-raf | 5 | 2022 | 222 | 0.320 |
Why?
|
| RNA-Binding Proteins | 5 | 2023 | 623 | 0.320 |
Why?
|
| DNA Transposable Elements | 6 | 2021 | 189 | 0.320 |
Why?
|
| Re-Irradiation | 2 | 2019 | 5 | 0.320 |
Why?
|
| Quality of Life | 7 | 2023 | 2162 | 0.320 |
Why?
|
| RNA, Small Nuclear | 2 | 2019 | 51 | 0.320 |
Why?
|
| DNA Replication | 4 | 2022 | 359 | 0.310 |
Why?
|
| Drug Delivery Systems | 4 | 2020 | 232 | 0.310 |
Why?
|
| Genes, p53 | 5 | 2013 | 234 | 0.310 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2025 | 145 | 0.310 |
Why?
|
| Telomere | 4 | 2020 | 231 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 18 | 2020 | 4881 | 0.300 |
Why?
|
| Neoplasms, Experimental | 5 | 2021 | 223 | 0.300 |
Why?
|
| Cell Self Renewal | 2 | 2021 | 50 | 0.290 |
Why?
|
| Microarray Analysis | 9 | 2021 | 239 | 0.290 |
Why?
|
| Blotting, Western | 13 | 2017 | 1138 | 0.290 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 4 | 2025 | 32 | 0.290 |
Why?
|
| RNA, Small Interfering | 7 | 2019 | 720 | 0.290 |
Why?
|
| Enhancer Elements, Genetic | 4 | 2019 | 323 | 0.280 |
Why?
|
| Ontario | 9 | 2024 | 91 | 0.280 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2020 | 20 | 0.280 |
Why?
|
| LIM-Homeodomain Proteins | 3 | 2025 | 42 | 0.280 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2020 | 91 | 0.280 |
Why?
|
| Cytoskeletal Proteins | 2 | 2010 | 284 | 0.270 |
Why?
|
| Small Molecule Libraries | 2 | 2019 | 138 | 0.270 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2020 | 262 | 0.270 |
Why?
|
| Disease Progression | 12 | 2025 | 2265 | 0.270 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2023 | 628 | 0.270 |
Why?
|
| Immunoglobulin G | 2 | 2025 | 810 | 0.270 |
Why?
|
| Neuroectodermal Tumors | 2 | 2018 | 13 | 0.270 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2020 | 63 | 0.270 |
Why?
|
| Reproducibility of Results | 10 | 2018 | 3056 | 0.270 |
Why?
|
| Gene Silencing | 5 | 2020 | 246 | 0.270 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2017 | 1332 | 0.270 |
Why?
|
| Anilides | 5 | 2019 | 58 | 0.260 |
Why?
|
| Canada | 4 | 2016 | 346 | 0.260 |
Why?
|
| Phosphoprotein Phosphatases | 3 | 2019 | 127 | 0.260 |
Why?
|
| Meninges | 2 | 2025 | 22 | 0.260 |
Why?
|
| HEK293 Cells | 6 | 2020 | 825 | 0.260 |
Why?
|
| Phosphorylation | 10 | 2023 | 1713 | 0.250 |
Why?
|
| Microsatellite Instability | 3 | 2022 | 40 | 0.250 |
Why?
|
| Genetic Heterogeneity | 4 | 2025 | 143 | 0.250 |
Why?
|
| Wnt Signaling Pathway | 2 | 2019 | 207 | 0.250 |
Why?
|
| Receptor, Notch1 | 2 | 2018 | 80 | 0.250 |
Why?
|
| Cranial Irradiation | 2 | 2017 | 72 | 0.240 |
Why?
|
| White Matter | 2 | 2020 | 212 | 0.240 |
Why?
|
| Multigene Family | 3 | 2019 | 324 | 0.240 |
Why?
|
| Mutagenesis, Insertional | 6 | 2021 | 157 | 0.240 |
Why?
|
| Brain | 7 | 2023 | 3225 | 0.240 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2025 | 29 | 0.240 |
Why?
|
| Pteridines | 3 | 2013 | 12 | 0.240 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 652 | 0.240 |
Why?
|
| Principal Component Analysis | 4 | 2017 | 160 | 0.230 |
Why?
|
| Shab Potassium Channels | 1 | 2025 | 5 | 0.230 |
Why?
|
| Spinal Cord | 3 | 2016 | 275 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2024 | 3867 | 0.230 |
Why?
|
| RNA Interference | 7 | 2018 | 548 | 0.230 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2025 | 21 | 0.230 |
Why?
|
| Zinc Finger Protein Gli2 | 4 | 2018 | 15 | 0.230 |
Why?
|
| SMARCB1 Protein | 4 | 2019 | 48 | 0.230 |
Why?
|
| Adenosine | 2 | 2024 | 140 | 0.230 |
Why?
|
| Vestibular Nerve | 2 | 2014 | 8 | 0.230 |
Why?
|
| Chromosome Mapping | 4 | 2023 | 1125 | 0.230 |
Why?
|
| Protein Kinases | 2 | 2017 | 345 | 0.230 |
Why?
|
| Cell Survival | 8 | 2025 | 890 | 0.230 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2024 | 456 | 0.230 |
Why?
|
| Quinolines | 5 | 2019 | 114 | 0.230 |
Why?
|
| Genetic Variation | 2 | 2021 | 1630 | 0.230 |
Why?
|
| GABAergic Neurons | 1 | 2025 | 64 | 0.230 |
Why?
|
| Plasma Cells | 1 | 2025 | 57 | 0.220 |
Why?
|
| Time Factors | 9 | 2021 | 6592 | 0.220 |
Why?
|
| Smad3 Protein | 3 | 2020 | 59 | 0.220 |
Why?
|
| Gene Deletion | 5 | 2020 | 811 | 0.220 |
Why?
|
| Neuroma, Acoustic | 2 | 2014 | 32 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 93 | 0.220 |
Why?
|
| Cell Plasticity | 1 | 2025 | 35 | 0.220 |
Why?
|
| Models, Genetic | 2 | 2018 | 790 | 0.220 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 2 | 2023 | 83 | 0.220 |
Why?
|
| Follow-Up Studies | 12 | 2025 | 5465 | 0.220 |
Why?
|
| Stem Cell Niche | 1 | 2024 | 58 | 0.220 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 1772 | 0.220 |
Why?
|
| Open Reading Frames | 1 | 2024 | 220 | 0.220 |
Why?
|
| Valproic Acid | 1 | 2025 | 168 | 0.220 |
Why?
|
| Sequence Analysis, RNA | 4 | 2024 | 424 | 0.220 |
Why?
|
| Nervous System Neoplasms | 1 | 2003 | 11 | 0.210 |
Why?
|
| Age of Onset | 6 | 2020 | 638 | 0.210 |
Why?
|
| Tuberous Sclerosis | 2 | 2015 | 124 | 0.210 |
Why?
|
| Endothelial Cells | 2 | 2024 | 539 | 0.210 |
Why?
|
| Coculture Techniques | 1 | 2024 | 246 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 10 | 3 | 2018 | 72 | 0.210 |
Why?
|
| Ifosfamide | 4 | 2020 | 35 | 0.210 |
Why?
|
| Indoles | 2 | 2015 | 204 | 0.210 |
Why?
|
| Loss of Function Mutation | 1 | 2025 | 162 | 0.210 |
Why?
|
| Genes, myc | 6 | 2019 | 107 | 0.210 |
Why?
|
| Base Sequence | 7 | 2017 | 3180 | 0.210 |
Why?
|
| Interneurons | 2 | 2025 | 147 | 0.210 |
Why?
|
| Phenotype | 11 | 2020 | 4605 | 0.200 |
Why?
|
| Molecular Biology | 1 | 2003 | 80 | 0.200 |
Why?
|
| Transplantation, Heterologous | 6 | 2019 | 276 | 0.200 |
Why?
|
| Mice, Knockout | 10 | 2025 | 4012 | 0.200 |
Why?
|
| Zebrafish Proteins | 1 | 2004 | 130 | 0.200 |
Why?
|
| Injections, Intraventricular | 2 | 2020 | 65 | 0.200 |
Why?
|
| Risk Factors | 14 | 2025 | 11184 | 0.200 |
Why?
|
| Human Genome Project | 1 | 2003 | 56 | 0.200 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 406 | 0.200 |
Why?
|
| Neoplasm Transplantation | 7 | 2020 | 399 | 0.200 |
Why?
|
| Cell Adhesion | 5 | 2020 | 360 | 0.200 |
Why?
|
| Radiotherapy | 3 | 2019 | 148 | 0.200 |
Why?
|
| Genes, Neoplasm | 3 | 2012 | 91 | 0.200 |
Why?
|
| Pediatrics | 3 | 2020 | 1221 | 0.200 |
Why?
|
| Gene Dosage | 4 | 2019 | 458 | 0.200 |
Why?
|
| Histone Deacetylases | 2 | 2016 | 125 | 0.200 |
Why?
|
| Trans-Activators | 3 | 2016 | 838 | 0.200 |
Why?
|
| Genes, Suppressor | 1 | 2002 | 12 | 0.190 |
Why?
|
| DNA-Directed DNA Polymerase | 2 | 2020 | 94 | 0.190 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2016 | 393 | 0.190 |
Why?
|
| Heterografts | 3 | 2017 | 201 | 0.190 |
Why?
|
| Case-Control Studies | 9 | 2024 | 3677 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2022 | 82 | 0.190 |
Why?
|
| Zinc Finger Protein Gli3 | 2 | 2021 | 8 | 0.190 |
Why?
|
| Genomic Structural Variation | 2 | 2014 | 92 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2025 | 415 | 0.190 |
Why?
|
| SOX9 Transcription Factor | 3 | 2022 | 87 | 0.190 |
Why?
|
| Gene Knockdown Techniques | 7 | 2020 | 399 | 0.190 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2016 | 21 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2019 | 148 | 0.190 |
Why?
|
| Congenital Abnormalities | 1 | 2025 | 298 | 0.190 |
Why?
|
| Neurosurgical Procedures | 3 | 2020 | 316 | 0.190 |
Why?
|
| Oligodendroglioma | 1 | 2021 | 25 | 0.190 |
Why?
|
| DNA Repair | 3 | 2022 | 638 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2020 | 212 | 0.190 |
Why?
|
| Diffusion Tensor Imaging | 4 | 2020 | 252 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 76 | 0.190 |
Why?
|
| Disease Management | 3 | 2024 | 567 | 0.190 |
Why?
|
| Databases, Genetic | 2 | 2010 | 507 | 0.180 |
Why?
|
| Transfection | 8 | 2018 | 1098 | 0.180 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2023 | 150 | 0.180 |
Why?
|
| Neoplasm Grading | 6 | 2020 | 308 | 0.180 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2019 | 71 | 0.180 |
Why?
|
| Receptors, Notch | 4 | 2025 | 214 | 0.180 |
Why?
|
| CD24 Antigen | 2 | 2019 | 33 | 0.180 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2025 | 503 | 0.180 |
Why?
|
| Frozen Sections | 2 | 2019 | 31 | 0.180 |
Why?
|
| Cell Cycle | 8 | 2019 | 624 | 0.180 |
Why?
|
| Proteome | 3 | 2018 | 282 | 0.180 |
Why?
|
| Middle Aged | 20 | 2021 | 29395 | 0.180 |
Why?
|
| Fetal Proteins | 1 | 2020 | 13 | 0.180 |
Why?
|
| Sequence Analysis, DNA | 5 | 2017 | 1835 | 0.180 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2018 | 16 | 0.170 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 2771 | 0.170 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2020 | 7 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2022 | 186 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 129 | 0.170 |
Why?
|
| Age Factors | 7 | 2018 | 2997 | 0.170 |
Why?
|
| PAX3 Transcription Factor | 1 | 2020 | 29 | 0.170 |
Why?
|
| Telomere Homeostasis | 1 | 2020 | 47 | 0.170 |
Why?
|
| Cerebral Ventricles | 1 | 2020 | 84 | 0.170 |
Why?
|
| Age Distribution | 2 | 2019 | 444 | 0.170 |
Why?
|
| Karyotyping | 2 | 2011 | 323 | 0.170 |
Why?
|
| Aneurysm, Ruptured | 1 | 2020 | 36 | 0.170 |
Why?
|
| Carboplatin | 3 | 2015 | 87 | 0.170 |
Why?
|
| Chromogranins | 1 | 2020 | 29 | 0.170 |
Why?
|
| Etoposide | 3 | 2015 | 120 | 0.170 |
Why?
|
| Pinealoma | 1 | 2020 | 23 | 0.170 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 203 | 0.160 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2020 | 559 | 0.160 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2020 | 71 | 0.160 |
Why?
|
| Tumor Escape | 1 | 2020 | 65 | 0.160 |
Why?
|
| Treatment Outcome | 11 | 2021 | 13098 | 0.160 |
Why?
|
| Chloride Channels | 1 | 2020 | 63 | 0.160 |
Why?
|
| Eye Movements | 1 | 2020 | 79 | 0.160 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2019 | 5 | 0.160 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2019 | 9 | 0.160 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2019 | 36 | 0.160 |
Why?
|
| Inhibin-beta Subunits | 1 | 2019 | 20 | 0.160 |
Why?
|
| Neuroepithelial Cells | 1 | 2019 | 9 | 0.160 |
Why?
|
| Enzyme Inhibitors | 4 | 2018 | 608 | 0.160 |
Why?
|
| Autocrine Communication | 1 | 2019 | 29 | 0.160 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2019 | 65 | 0.160 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2019 | 15 | 0.160 |
Why?
|
| Photons | 1 | 2019 | 53 | 0.160 |
Why?
|
| Down-Regulation | 3 | 2011 | 718 | 0.160 |
Why?
|
| Osteoblasts | 1 | 2020 | 166 | 0.160 |
Why?
|
| Nervous System | 1 | 2020 | 131 | 0.160 |
Why?
|
| Spliceosomes | 1 | 2019 | 57 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2016 | 510 | 0.150 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2020 | 66 | 0.150 |
Why?
|
| Japan | 2 | 2020 | 155 | 0.150 |
Why?
|
| Forecasting | 2 | 2015 | 377 | 0.150 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2019 | 14 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 6 | 2020 | 676 | 0.150 |
Why?
|
| Whole Genome Sequencing | 2 | 2019 | 325 | 0.150 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2019 | 124 | 0.150 |
Why?
|
| Clone Cells | 2 | 2017 | 180 | 0.150 |
Why?
|
| Receptors, GABA-A | 1 | 2019 | 59 | 0.150 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 41 | 0.150 |
Why?
|
| Nucleic Acids | 1 | 2019 | 27 | 0.150 |
Why?
|
| Receptor, ErbB-4 | 1 | 2018 | 9 | 0.150 |
Why?
|
| ras Proteins | 2 | 2020 | 146 | 0.150 |
Why?
|
| Casein Kinase II | 1 | 2018 | 15 | 0.150 |
Why?
|
| Executive Function | 2 | 2020 | 126 | 0.150 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2019 | 139 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 239 | 0.150 |
Why?
|
| Histone Chaperones | 1 | 2018 | 12 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2020 | 448 | 0.150 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 57 | 0.150 |
Why?
|
| Phosphoproteins | 2 | 2018 | 458 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2019 | 331 | 0.150 |
Why?
|
| Pluripotent Stem Cells | 1 | 2019 | 79 | 0.150 |
Why?
|
| Postoperative Period | 1 | 2019 | 339 | 0.150 |
Why?
|
| Intraoperative Care | 1 | 2019 | 120 | 0.150 |
Why?
|
| RNA | 5 | 2024 | 607 | 0.150 |
Why?
|
| Cyclin-Dependent Kinases | 3 | 2015 | 90 | 0.150 |
Why?
|
| MyoD Protein | 2 | 2019 | 26 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 77 | 0.150 |
Why?
|
| Benzodiazepines | 1 | 2019 | 112 | 0.150 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2018 | 53 | 0.150 |
Why?
|
| Parabiosis | 1 | 2018 | 3 | 0.150 |
Why?
|
| Zebrafish | 1 | 2021 | 421 | 0.140 |
Why?
|
| Genome-Wide Association Study | 5 | 2018 | 1880 | 0.140 |
Why?
|
| Glutathione Transferase | 1 | 2019 | 163 | 0.140 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2018 | 60 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 196 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2019 | 104 | 0.140 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 111 | 0.140 |
Why?
|
| Rubinstein-Taybi Syndrome | 1 | 2018 | 17 | 0.140 |
Why?
|
| src-Family Kinases | 1 | 2018 | 97 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 5 | 2022 | 236 | 0.140 |
Why?
|
| Lysosomes | 1 | 2020 | 266 | 0.140 |
Why?
|
| Cell Growth Processes | 4 | 2013 | 69 | 0.140 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 66 | 0.140 |
Why?
|
| Acetyltransferases | 1 | 2018 | 92 | 0.140 |
Why?
|
| 5-Methylcytosine | 1 | 2018 | 34 | 0.140 |
Why?
|
| Receptors, Virus | 1 | 2018 | 111 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 401 | 0.140 |
Why?
|
| Rats, Nude | 1 | 2017 | 11 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2024 | 512 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2016 | 118 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 17 | 4 | 2013 | 374 | 0.140 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2017 | 4 | 0.140 |
Why?
|
| Methylation | 3 | 2012 | 232 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2019 | 202 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2019 | 188 | 0.140 |
Why?
|
| Cell Tracking | 1 | 2017 | 17 | 0.140 |
Why?
|
| Neuroimaging | 2 | 2017 | 376 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 134 | 0.140 |
Why?
|
| Genetic Association Studies | 2 | 2019 | 868 | 0.140 |
Why?
|
| Cells, Cultured | 7 | 2020 | 3180 | 0.140 |
Why?
|
| Pyruvate Kinase | 1 | 2017 | 11 | 0.140 |
Why?
|
| Cell Size | 2 | 2020 | 90 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 45 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 78 | 0.140 |
Why?
|
| Iron | 1 | 2020 | 305 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 701 | 0.140 |
Why?
|
| Glypicans | 1 | 2017 | 41 | 0.140 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2019 | 235 | 0.140 |
Why?
|
| Phosphotyrosine | 1 | 2017 | 31 | 0.130 |
Why?
|
| Models, Biological | 6 | 2020 | 1538 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 2315 | 0.130 |
Why?
|
| CD47 Antigen | 1 | 2017 | 11 | 0.130 |
Why?
|
| Manganese Poisoning | 1 | 2016 | 4 | 0.130 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2017 | 86 | 0.130 |
Why?
|
| Allografts | 1 | 2018 | 198 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2021 | 963 | 0.130 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 69 | 0.130 |
Why?
|
| Radiation Injuries | 2 | 2019 | 166 | 0.130 |
Why?
|
| Frizzled Receptors | 1 | 2016 | 20 | 0.130 |
Why?
|
| Flow Cytometry | 6 | 2019 | 824 | 0.130 |
Why?
|
| Neural Pathways | 2 | 2015 | 283 | 0.130 |
Why?
|
| Mitosis | 2 | 2020 | 205 | 0.130 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 519 | 0.130 |
Why?
|
| Caenorhabditis elegans | 2 | 2021 | 244 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 297 | 0.130 |
Why?
|
| Proteogenomics | 1 | 2018 | 110 | 0.130 |
Why?
|
| Syndrome | 1 | 2019 | 1176 | 0.130 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.130 |
Why?
|
| Cellular Senescence | 2 | 2016 | 201 | 0.130 |
Why?
|
| F-Box Proteins | 1 | 2016 | 38 | 0.130 |
Why?
|
| Manganese | 1 | 2016 | 61 | 0.130 |
Why?
|
| International Cooperation | 3 | 2014 | 169 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1161 | 0.130 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 128 | 0.130 |
Why?
|
| Blood-Brain Barrier | 3 | 2025 | 157 | 0.130 |
Why?
|
| Pyridines | 4 | 2019 | 251 | 0.130 |
Why?
|
| Heat-Shock Proteins | 1 | 2017 | 204 | 0.130 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 1312 | 0.120 |
Why?
|
| United States | 7 | 2025 | 11777 | 0.120 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2016 | 48 | 0.120 |
Why?
|
| Phagocytosis | 1 | 2017 | 194 | 0.120 |
Why?
|
| Thioridazine | 1 | 2015 | 4 | 0.120 |
Why?
|
| Intermediate Filament Proteins | 2 | 2012 | 27 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 447 | 0.120 |
Why?
|
| Protein Biosynthesis | 2 | 2016 | 678 | 0.120 |
Why?
|
| Meningioma | 1 | 2017 | 141 | 0.120 |
Why?
|
| Antibodies | 1 | 2017 | 375 | 0.120 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2012 | 580 | 0.120 |
Why?
|
| Occupational Exposure | 1 | 2016 | 139 | 0.120 |
Why?
|
| Longitudinal Studies | 5 | 2019 | 1510 | 0.120 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2014 | 160 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 6 | 2017 | 1626 | 0.120 |
Why?
|
| Hexokinase | 1 | 2015 | 25 | 0.120 |
Why?
|
| Aurora Kinase B | 1 | 2015 | 8 | 0.120 |
Why?
|
| Eye Proteins | 1 | 2016 | 234 | 0.120 |
Why?
|
| Base Pair Mismatch | 1 | 2015 | 22 | 0.120 |
Why?
|
| Proteins | 2 | 2018 | 1100 | 0.120 |
Why?
|
| Selection, Genetic | 1 | 2016 | 169 | 0.120 |
Why?
|
| Third Ventricle | 1 | 2014 | 33 | 0.110 |
Why?
|
| Lithium | 1 | 2014 | 71 | 0.110 |
Why?
|
| Software | 3 | 2020 | 735 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 105 | 0.110 |
Why?
|
| Niacinamide | 1 | 2014 | 31 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2016 | 1735 | 0.110 |
Why?
|
| DNA Glycosylases | 1 | 2014 | 33 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 135 | 0.110 |
Why?
|
| Infant, Newborn | 8 | 2025 | 8635 | 0.110 |
Why?
|
| Molecular Sequence Data | 5 | 2016 | 3978 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2016 | 827 | 0.110 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2014 | 104 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 62 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 5 | 2014 | 546 | 0.110 |
Why?
|
| Lymphoma, Follicular | 1 | 2014 | 30 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2016 | 272 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2025 | 406 | 0.110 |
Why?
|
| International Agencies | 1 | 2013 | 31 | 0.110 |
Why?
|
| Prosencephalon | 3 | 2020 | 43 | 0.110 |
Why?
|
| Quinazolines | 1 | 2015 | 185 | 0.110 |
Why?
|
| Sequence Deletion | 2 | 2009 | 541 | 0.110 |
Why?
|
| X Chromosome Inactivation | 1 | 2013 | 66 | 0.110 |
Why?
|
| Elongation Factor 2 Kinase | 1 | 2013 | 5 | 0.100 |
Why?
|
| Peptide Chain Elongation, Translational | 1 | 2013 | 5 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2022 | 432 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2013 | 38 | 0.100 |
Why?
|
| NFI Transcription Factors | 1 | 2013 | 54 | 0.100 |
Why?
|
| Aurora Kinase A | 1 | 2013 | 38 | 0.100 |
Why?
|
| Sirolimus | 1 | 2015 | 239 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 572 | 0.100 |
Why?
|
| Cognition Disorders | 2 | 2015 | 579 | 0.100 |
Why?
|
| Aged | 9 | 2018 | 21789 | 0.100 |
Why?
|
| Biomarkers | 3 | 2019 | 3431 | 0.100 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 56 | 0.100 |
Why?
|
| Sarcoma | 1 | 2015 | 209 | 0.100 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 130 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 532 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 317 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2013 | 71 | 0.100 |
Why?
|
| Gene Expression | 4 | 2020 | 1622 | 0.100 |
Why?
|
| Formaldehyde | 1 | 2013 | 39 | 0.100 |
Why?
|
| Neuroanatomy | 1 | 2012 | 13 | 0.100 |
Why?
|
| Chromosomes, Human, X | 1 | 2013 | 161 | 0.100 |
Why?
|
| Cell Line | 5 | 2020 | 2863 | 0.100 |
Why?
|
| Europe | 1 | 2013 | 382 | 0.100 |
Why?
|
| Cyclin D | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cell Death | 3 | 2019 | 251 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2018 | 385 | 0.100 |
Why?
|
| Genetic Therapy | 1 | 2017 | 738 | 0.090 |
Why?
|
| Electrophoresis, Capillary | 1 | 2012 | 13 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2015 | 482 | 0.090 |
Why?
|
| Sulfites | 1 | 2012 | 31 | 0.090 |
Why?
|
| Chromatography, Thin Layer | 1 | 2012 | 50 | 0.090 |
Why?
|
| DNA Restriction Enzymes | 1 | 2012 | 122 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 198 | 0.090 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 783 | 0.090 |
Why?
|
| Follistatin-Related Proteins | 1 | 2011 | 2 | 0.090 |
Why?
|
| Supratentorial Neoplasms | 1 | 2012 | 40 | 0.090 |
Why?
|
| Heart Function Tests | 1 | 2011 | 57 | 0.090 |
Why?
|
| Cytosine | 1 | 2012 | 59 | 0.090 |
Why?
|
| Chromosomes | 2 | 2023 | 164 | 0.090 |
Why?
|
| Cerebellar Diseases | 1 | 2012 | 81 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2012 | 100 | 0.090 |
Why?
|
| Cell Division | 3 | 2020 | 773 | 0.090 |
Why?
|
| Empyema, Subdural | 1 | 2011 | 8 | 0.090 |
Why?
|
| Proteoglycans | 1 | 2011 | 94 | 0.090 |
Why?
|
| Streptococcus anginosus | 1 | 2011 | 10 | 0.090 |
Why?
|
| Epidural Abscess | 1 | 2011 | 12 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2011 | 71 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 114 | 0.090 |
Why?
|
| Chromatography, Liquid | 3 | 2018 | 245 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2019 | 30 | 0.090 |
Why?
|
| Probability | 1 | 2011 | 334 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2023 | 6610 | 0.090 |
Why?
|
| Angiography | 1 | 2011 | 215 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 1486 | 0.090 |
Why?
|
| History, 20th Century | 2 | 2010 | 396 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2025 | 303 | 0.090 |
Why?
|
| Exome | 2 | 2013 | 1087 | 0.090 |
Why?
|
| Thrombospondin 1 | 1 | 2010 | 25 | 0.090 |
Why?
|
| Rats | 1 | 2017 | 3876 | 0.090 |
Why?
|
| Cell Compartmentation | 1 | 2010 | 41 | 0.080 |
Why?
|
| Medical Oncology | 2 | 2024 | 247 | 0.080 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2021 | 37 | 0.080 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 1391 | 0.080 |
Why?
|
| Cerebral Hemorrhage | 1 | 2011 | 156 | 0.080 |
Why?
|
| Meningitis, Bacterial | 1 | 2011 | 98 | 0.080 |
Why?
|
| Morpholines | 3 | 2016 | 64 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2017 | 3752 | 0.080 |
Why?
|
| Postoperative Complications | 5 | 2024 | 3170 | 0.080 |
Why?
|
| Pyrazoles | 3 | 2019 | 333 | 0.080 |
Why?
|
| Azacitidine | 1 | 2010 | 53 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2010 | 152 | 0.080 |
Why?
|
| Mass Spectrometry | 3 | 2017 | 367 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 411 | 0.080 |
Why?
|
| Radiotherapy Dosage | 3 | 2016 | 233 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 62 | 0.080 |
Why?
|
| RNA Splice Sites | 2 | 2019 | 99 | 0.080 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 79 | 0.080 |
Why?
|
| Drosophila melanogaster | 3 | 2021 | 845 | 0.080 |
Why?
|
| Genetics, Medical | 1 | 2010 | 123 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 3119 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2016 | 353 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2018 | 1087 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2010 | 277 | 0.070 |
Why?
|
| RNA, Neoplasm | 3 | 2017 | 146 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 380 | 0.070 |
Why?
|
| Streptococcal Infections | 1 | 2011 | 248 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2014 | 115 | 0.070 |
Why?
|
| Spheroids, Cellular | 3 | 2013 | 63 | 0.070 |
Why?
|
| Neuropsychological Tests | 3 | 2020 | 991 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1044 | 0.070 |
Why?
|
| Anisotropy | 2 | 2020 | 126 | 0.070 |
Why?
|
| Datasets as Topic | 2 | 2019 | 105 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2012 | 50 | 0.070 |
Why?
|
| Protein Binding | 2 | 2024 | 1860 | 0.070 |
Why?
|
| Peptides | 2 | 2024 | 864 | 0.070 |
Why?
|
| RNA Splicing | 2 | 2019 | 252 | 0.070 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 556 | 0.070 |
Why?
|
| Atlanto-Occipital Joint | 1 | 2007 | 6 | 0.070 |
Why?
|
| Homeostasis | 2 | 2023 | 751 | 0.070 |
Why?
|
| NF-kappa B | 2 | 2025 | 483 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 3 | 2014 | 324 | 0.070 |
Why?
|
| Atlanto-Axial Joint | 1 | 2007 | 22 | 0.070 |
Why?
|
| T-Box Domain Proteins | 2 | 2022 | 124 | 0.070 |
Why?
|
| Developmental Disabilities | 1 | 2012 | 742 | 0.070 |
Why?
|
| Bone Screws | 1 | 2007 | 53 | 0.070 |
Why?
|
| Muscle Proteins | 2 | 2022 | 427 | 0.070 |
Why?
|
| Microsatellite Repeats | 2 | 2022 | 241 | 0.070 |
Why?
|
| Retreatment | 2 | 2021 | 92 | 0.070 |
Why?
|
| Models, Molecular | 3 | 2018 | 1147 | 0.070 |
Why?
|
| Machine Learning | 2 | 2022 | 339 | 0.070 |
Why?
|
| Joint Instability | 1 | 2007 | 59 | 0.070 |
Why?
|
| Incidence | 1 | 2014 | 3421 | 0.070 |
Why?
|
| Logistic Models | 1 | 2011 | 1908 | 0.060 |
Why?
|
| Retinoblastoma Protein | 2 | 2020 | 86 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2019 | 116 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2019 | 259 | 0.060 |
Why?
|
| Translocation, Genetic | 2 | 2012 | 363 | 0.060 |
Why?
|
| Intelligence Tests | 2 | 2019 | 63 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2203 | 0.060 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 121 | 0.060 |
Why?
|
| Spinal Fusion | 1 | 2007 | 115 | 0.060 |
Why?
|
| NIH 3T3 Cells | 2 | 2018 | 97 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 573 | 0.060 |
Why?
|
| Pyrimidinones | 2 | 2018 | 59 | 0.060 |
Why?
|
| Transcription Factor HES-1 | 2 | 2019 | 20 | 0.060 |
Why?
|
| Astrocytes | 2 | 2020 | 273 | 0.060 |
Why?
|
| Live Birth | 1 | 2025 | 72 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 1982 | 0.060 |
Why?
|
| Global Health | 2 | 2021 | 623 | 0.060 |
Why?
|
| Lateral Ventricles | 1 | 2025 | 16 | 0.060 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2025 | 45 | 0.060 |
Why?
|
| Emotions | 2 | 2020 | 365 | 0.060 |
Why?
|
| Receptors, CCR2 | 1 | 2025 | 27 | 0.060 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2024 | 5 | 0.060 |
Why?
|
| Registries | 2 | 2025 | 1586 | 0.060 |
Why?
|
| Cisplatin | 2 | 2016 | 287 | 0.060 |
Why?
|
| Mice, Mutant Strains | 2 | 2017 | 400 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2011 | 890 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2016 | 948 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2025 | 64 | 0.060 |
Why?
|
| Inflammation | 2 | 2025 | 1595 | 0.060 |
Why?
|
| Chromosomes, Human | 2 | 2017 | 137 | 0.060 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2004 | 15 | 0.060 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2016 | 207 | 0.060 |
Why?
|
| Acetylation | 1 | 2025 | 195 | 0.060 |
Why?
|
| Gene Fusion | 2 | 2015 | 61 | 0.050 |
Why?
|
| Receptors, CCR7 | 1 | 2024 | 22 | 0.050 |
Why?
|
| Ligases | 1 | 2023 | 48 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 1492 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2024 | 83 | 0.050 |
Why?
|
| Echo-Planar Imaging | 1 | 2003 | 23 | 0.050 |
Why?
|
| COS Cells | 2 | 2015 | 284 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 397 | 0.050 |
Why?
|
| Purkinje Cells | 1 | 2025 | 166 | 0.050 |
Why?
|
| Cytogenetics | 2 | 2014 | 18 | 0.050 |
Why?
|
| Cyclin D1 | 2 | 2014 | 123 | 0.050 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2022 | 3 | 0.050 |
Why?
|
| DNA Primers | 2 | 2014 | 672 | 0.050 |
Why?
|
| Medical Informatics Applications | 1 | 2003 | 24 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2024 | 295 | 0.050 |
Why?
|
| Feedback | 1 | 2024 | 173 | 0.050 |
Why?
|
| Leukemia, Lymphoid | 1 | 2003 | 108 | 0.050 |
Why?
|
| Core Binding Factor alpha Subunits | 1 | 2022 | 5 | 0.050 |
Why?
|
| Biotechnology | 1 | 2003 | 61 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2024 | 358 | 0.050 |
Why?
|
| Telencephalon | 1 | 2022 | 11 | 0.050 |
Why?
|
| Dyneins | 1 | 2022 | 13 | 0.050 |
Why?
|
| Nestin | 2 | 2012 | 19 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 358 | 0.050 |
Why?
|
| Hospitals, Pediatric | 1 | 2007 | 795 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 119 | 0.050 |
Why?
|
| Holoprosencephaly | 1 | 2002 | 24 | 0.050 |
Why?
|
| Consensus Sequence | 1 | 2002 | 59 | 0.050 |
Why?
|
| Connectome | 1 | 2024 | 118 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2023 | 161 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2014 | 651 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2013 | 433 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 201 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 29 | 0.050 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2025 | 277 | 0.050 |
Why?
|
| Imidazoles | 2 | 2014 | 220 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 1301 | 0.050 |
Why?
|
| Point Mutation | 2 | 2015 | 362 | 0.050 |
Why?
|
| Microglia | 1 | 2023 | 139 | 0.050 |
Why?
|
| LIM Domain Proteins | 2 | 2012 | 64 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 204 | 0.040 |
Why?
|
| Nerve Net | 1 | 2024 | 259 | 0.040 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2020 | 2 | 0.040 |
Why?
|
| Systems Biology | 1 | 2021 | 63 | 0.040 |
Why?
|
| Drosophila | 2 | 2016 | 829 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 158 | 0.040 |
Why?
|
| Protein Interaction Mapping | 1 | 2021 | 94 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2020 | 10 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2021 | 91 | 0.040 |
Why?
|
| Cholesterol | 1 | 2024 | 574 | 0.040 |
Why?
|
| Heart Failure | 1 | 2014 | 2439 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 7232 | 0.040 |
Why?
|
| PAX6 Transcription Factor | 1 | 2020 | 39 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 2170 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 2020 | 66 | 0.040 |
Why?
|
| Nortriptyline | 1 | 2020 | 7 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2020 | 46 | 0.040 |
Why?
|
| Survivors | 1 | 2023 | 358 | 0.040 |
Why?
|
| Species Specificity | 2 | 2012 | 570 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 97 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2020 | 30 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 2020 | 79 | 0.040 |
Why?
|
| Genes, Homeobox | 1 | 2020 | 72 | 0.040 |
Why?
|
| AC133 Antigen | 1 | 2020 | 37 | 0.040 |
Why?
|
| Cerebral Angiography | 1 | 2020 | 106 | 0.040 |
Why?
|
| Internet | 1 | 2003 | 403 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 779 | 0.040 |
Why?
|
| Risk | 2 | 2014 | 833 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 138 | 0.040 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2019 | 23 | 0.040 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2020 | 104 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 128 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2020 | 50 | 0.040 |
Why?
|
| Protons | 1 | 2020 | 99 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2793 | 0.040 |
Why?
|
| Pimozide | 1 | 2019 | 7 | 0.040 |
Why?
|
| Craniopharyngioma | 1 | 2020 | 35 | 0.040 |
Why?
|
| Neurosciences | 1 | 2020 | 54 | 0.040 |
Why?
|
| Receptor, trkA | 1 | 2019 | 18 | 0.040 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Smad2 Protein | 1 | 2019 | 53 | 0.040 |
Why?
|
| RNA Splicing Factors | 1 | 2019 | 55 | 0.040 |
Why?
|
| B7 Antigens | 1 | 2019 | 14 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2019 | 76 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 2019 | 42 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 130 | 0.040 |
Why?
|
| Pedigree | 2 | 2018 | 1732 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 110 | 0.040 |
Why?
|
| Ribonuclease III | 1 | 2019 | 103 | 0.040 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2018 | 6 | 0.040 |
Why?
|
| Integrases | 1 | 2020 | 163 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2019 | 123 | 0.040 |
Why?
|
| Allosteric Regulation | 1 | 2019 | 64 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 2669 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2019 | 116 | 0.040 |
Why?
|
| Phenazines | 1 | 2018 | 9 | 0.040 |
Why?
|
| Naphthyridines | 1 | 2018 | 10 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2020 | 227 | 0.040 |
Why?
|
| Attention | 1 | 2020 | 202 | 0.040 |
Why?
|
| Annexin A5 | 1 | 2018 | 16 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 15 | 0.040 |
Why?
|
| Autism Spectrum Disorder | 1 | 2024 | 429 | 0.040 |
Why?
|
| Twist-Related Protein 1 | 1 | 2018 | 39 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 92 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2020 | 467 | 0.040 |
Why?
|
| Macrophages | 1 | 2023 | 710 | 0.040 |
Why?
|
| Heredity | 1 | 2018 | 16 | 0.040 |
Why?
|
| Snail Family Transcription Factors | 1 | 2018 | 26 | 0.040 |
Why?
|
| Child Health | 1 | 2019 | 68 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 63 | 0.040 |
Why?
|
| Unsupervised Machine Learning | 1 | 2018 | 14 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 110 | 0.040 |
Why?
|
| Genetic Techniques | 1 | 2018 | 109 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 398 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2018 | 97 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 426 | 0.040 |
Why?
|
| Proton Therapy | 1 | 2019 | 151 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2018 | 115 | 0.040 |
Why?
|
| rho-Associated Kinases | 1 | 2018 | 57 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 616 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 2017 | 21 | 0.030 |
Why?
|
| Diencephalon | 1 | 2017 | 11 | 0.030 |
Why?
|
| DNA Polymerase III | 1 | 2017 | 29 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2017 | 79 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 2017 | 38 | 0.030 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 31 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2019 | 93 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2017 | 60 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2018 | 109 | 0.030 |
Why?
|
| Cytokines | 1 | 2024 | 1397 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 169 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 504 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 4006 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 72 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2019 | 252 | 0.030 |
Why?
|
| Health Status | 1 | 2019 | 413 | 0.030 |
Why?
|
| Reoperation | 2 | 2011 | 851 | 0.030 |
Why?
|
| Metaphase | 1 | 2017 | 35 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2017 | 33 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2017 | 103 | 0.030 |
Why?
|
| District of Columbia | 1 | 2016 | 17 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2016 | 24 | 0.030 |
Why?
|
| Benzodiazepinones | 1 | 2016 | 1 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2017 | 94 | 0.030 |
Why?
|
| Methionine | 1 | 2017 | 105 | 0.030 |
Why?
|
| Chromones | 1 | 2016 | 26 | 0.030 |
Why?
|
| Dasatinib | 1 | 2016 | 50 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2016 | 21 | 0.030 |
Why?
|
| Autophagy | 1 | 2020 | 429 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2016 | 66 | 0.030 |
Why?
|
| California | 1 | 2016 | 144 | 0.030 |
Why?
|
| Genotype | 2 | 2013 | 2822 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 74 | 0.030 |
Why?
|
| Hearing | 1 | 2016 | 62 | 0.030 |
Why?
|
| Thiophenes | 1 | 2016 | 72 | 0.030 |
Why?
|
| Embryonic Development | 1 | 2018 | 224 | 0.030 |
Why?
|
| Benzamides | 1 | 2016 | 125 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 21 | 0.030 |
Why?
|
| Neurofibromatoses | 1 | 2015 | 10 | 0.030 |
Why?
|
| Acetophenones | 1 | 2015 | 13 | 0.030 |
Why?
|
| Flunarizine | 1 | 2015 | 3 | 0.030 |
Why?
|
| Dioxolanes | 1 | 2015 | 12 | 0.030 |
Why?
|
| Phthalazines | 1 | 2015 | 15 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1470 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 1041 | 0.030 |
Why?
|
| Benzopyrans | 1 | 2015 | 21 | 0.030 |
Why?
|
| Indazoles | 1 | 2015 | 31 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 186 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 294 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 173 | 0.030 |
Why?
|
| Urea | 1 | 2016 | 238 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2015 | 27 | 0.030 |
Why?
|
| Pons | 1 | 2015 | 35 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 210 | 0.030 |
Why?
|
| Jagged-2 Protein | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2017 | 487 | 0.030 |
Why?
|
| Problem Solving | 1 | 2015 | 67 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2015 | 81 | 0.030 |
Why?
|
| RNAi Therapeutics | 1 | 2015 | 18 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 187 | 0.030 |
Why?
|
| X-linked Nuclear Protein | 1 | 2014 | 19 | 0.030 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Plicamycin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2014 | 3 | 0.030 |
Why?
|
| Triazines | 1 | 2014 | 33 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 37 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 337 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2015 | 196 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2015 | 136 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 2014 | 71 | 0.030 |
Why?
|
| Drug Design | 1 | 2015 | 168 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 46 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2014 | 21 | 0.030 |
Why?
|
| Schwann Cells | 1 | 2014 | 68 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2014 | 21 | 0.030 |
Why?
|
| Leukemia | 1 | 2017 | 377 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2014 | 94 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 99 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 57 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2020 | 773 | 0.030 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 150 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 367 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 63 | 0.030 |
Why?
|
| Azepines | 1 | 2014 | 65 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2014 | 90 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 143 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2014 | 263 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 249 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 57 | 0.030 |
Why?
|
| Piperazines | 1 | 2015 | 256 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2014 | 116 | 0.030 |
Why?
|
| S Phase | 1 | 2013 | 78 | 0.030 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 160 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2014 | 103 | 0.030 |
Why?
|
| Piperidines | 1 | 2015 | 240 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 723 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2013 | 83 | 0.030 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2013 | 11 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2013 | 34 | 0.030 |
Why?
|
| Food Deprivation | 1 | 2013 | 34 | 0.030 |
Why?
|
| Australia | 1 | 2013 | 186 | 0.030 |
Why?
|
| Triazoles | 1 | 2014 | 142 | 0.030 |
Why?
|
| Heart Conduction System | 1 | 2014 | 149 | 0.030 |
Why?
|
| Germany | 1 | 2013 | 60 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 198 | 0.030 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 6 | 0.030 |
Why?
|
| Tetraploidy | 1 | 2012 | 4 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 258 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2014 | 190 | 0.030 |
Why?
|
| Cell Shape | 1 | 2013 | 70 | 0.030 |
Why?
|
| Cathepsin B | 1 | 2012 | 12 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 319 | 0.030 |
Why?
|
| Rituximab | 1 | 2014 | 165 | 0.030 |
Why?
|
| Argonaute Proteins | 1 | 2012 | 31 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2013 | 141 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2013 | 402 | 0.020 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2012 | 12 | 0.020 |
Why?
|
| Mass Screening | 1 | 2019 | 843 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 259 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2013 | 110 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 145 | 0.020 |
Why?
|
| TCF Transcription Factors | 1 | 2012 | 19 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 362 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 69 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 256 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2012 | 29 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2013 | 433 | 0.020 |
Why?
|
| Polyploidy | 1 | 2012 | 19 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 233 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2013 | 261 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 128 | 0.020 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 62 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 986 | 0.020 |
Why?
|
| Fibrosis | 1 | 2014 | 461 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2012 | 72 | 0.020 |
Why?
|
| Luciferases | 1 | 2012 | 139 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2012 | 69 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 454 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 163 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2013 | 482 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 206 | 0.020 |
Why?
|
| Cell Migration Assays | 1 | 2011 | 3 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 183 | 0.020 |
Why?
|
| Exons | 1 | 2015 | 839 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2013 | 367 | 0.020 |
Why?
|
| Protein Phosphatase 2C | 1 | 2012 | 60 | 0.020 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2014 | 232 | 0.020 |
Why?
|
| Melanoma | 1 | 2019 | 969 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2013 | 220 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 310 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 182 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2011 | 60 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2012 | 60 | 0.020 |
Why?
|
| Autopsy | 1 | 2011 | 120 | 0.020 |
Why?
|
| Trephining | 1 | 2011 | 2 | 0.020 |
Why?
|
| Brain Stem | 1 | 2012 | 119 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 10 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2013 | 838 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 296 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 874 | 0.020 |
Why?
|
| DNA Damage | 1 | 2014 | 547 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2012 | 220 | 0.020 |
Why?
|
| Binding Sites | 1 | 2014 | 1386 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 874 | 0.020 |
Why?
|
| Receptor, EphB2 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 819 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2011 | 204 | 0.020 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2010 | 7 | 0.020 |
Why?
|
| Craniotomy | 1 | 2011 | 106 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 372 | 0.020 |
Why?
|
| Brain Damage, Chronic | 1 | 2010 | 31 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 787 | 0.020 |
Why?
|
| Intellectual Property | 1 | 2010 | 9 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2014 | 1041 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3758 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2009 | 80 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 571 | 0.020 |
Why?
|
| Drainage | 1 | 2011 | 265 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2011 | 272 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2010 | 399 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2014 | 804 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 596 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 519 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2011 | 535 | 0.020 |
Why?
|
| Myocardium | 1 | 2014 | 1041 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2008 | 37 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 1221 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2008 | 38 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 365 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2010 | 249 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 753 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 390 | 0.020 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2008 | 10 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 1783 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2010 | 285 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 1338 | 0.020 |
Why?
|
| Gestational Age | 1 | 2012 | 1230 | 0.020 |
Why?
|
| Joint Dislocations | 1 | 2007 | 24 | 0.020 |
Why?
|
| History, 19th Century | 1 | 2007 | 120 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 1724 | 0.020 |
Why?
|
| Synapses | 1 | 2010 | 470 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 559 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 1132 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 1421 | 0.020 |
Why?
|
| Heart-Assist Devices | 1 | 2014 | 1101 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 1308 | 0.010 |
Why?
|
| Cyclin D2 | 1 | 2004 | 15 | 0.010 |
Why?
|
| High Mobility Group Proteins | 1 | 2004 | 33 | 0.010 |
Why?
|
| SOXC Transcription Factors | 1 | 2004 | 13 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 902 | 0.010 |
Why?
|
| Cyclins | 1 | 2004 | 105 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 563 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2003 | 50 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2003 | 222 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 272 | 0.010 |
Why?
|
| Hypertension | 1 | 2011 | 1407 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 109 | 0.010 |
Why?
|
| Patient Selection | 1 | 2006 | 734 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 485 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 1685 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 2588 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2003 | 1187 | 0.010 |
Why?
|